Shares of AstraZeneca fell 8per cent early on Monday, hit by doubts about the British firm’s strategy and speculation of a rival bid after it announced the US$39 billion purchase of Alexion Pharmaceuticals over the weekend.
AstraZeneca shares sink 8per cent after US$39 billion Alexion buyout
